INTRA-CELLULAR
PharmaINTRA-CELLULAR is a pharmaceutical company focused on Neurology, Cardiovascular. Key products include CAPLYTA.
FDA Novel Drug Designations
(2019)See 1 novel approval →
INTRA-CELLULAR at a Glance
- Growing R&D activity with 12 trials in last 2 years
- Fast trial execution (16 months median completion)
INTRA-CELLULAR's Key Drugs
INTRA-CELLULAR's core commercial portfolio centers on CAPLYTA, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
INTRA-CELLULAR's Recent FDA Approvals
New NDA/BLA approvals for INTRA-CELLULAR over the last two years — novel drugs only, excluding generics and label supplements.
INTRA-CELLULAR's Therapeutic Areas
INTRA-CELLULAR's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
INTRA-CELLULAR's Top Competitors
INTRA-CELLULAR's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
INTRA-CELLULAR Pipeline Snapshot
INTRA-CELLULAR has 7 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 3 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 10/18 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-12-20
- Latest
- 2026-04-24
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges